fda import alert semaglutide tirzepatide green list 🚨Big shifts in the GLP-1 landscape🚨 - Important FDA update on GLP-1

That is where the next GLP-1 battle gets fought

Feb 28, 2026 On paper, cagrilintide and retatrutide look like they belong to the same family

That's the precise research question that would most directly answer what women on GLP-1 therapy want to know - and it hasn't been done

1,2 Most side effects are mild to moderate, appear during the period when the dose is increased (titration), and resolve over four to six weeks once the body adjusts

Regular review of weight loss progress, typically every three months, allows assessment of treatment response and consideration of whether continuation is appropriate according to NICE TA875, which recommends discontinuation if less than 5% weight loss is achieved after six months at the maintenance dose